pegloticase

CHEBI:CHEBI_753480

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

generic_name
pegloticase
rxcui
1011657
product_type
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
dosage_form
INJECTION, SOLUTION
route
INTRAVENOUS
marketing_category
DRUG FOR FURTHER PROCESSING
active_ingredient_strength
8 mg/mL
labeler_name
Bio-Technology General (Israel) Ltd.
manufacturer_name
Horizon Therapeutics USA, Inc.
marketing_start_date
20100914
package_marketing_start_date
20100914
brand_name
Krystexxa
brand_name_base
Krystexxa
product_ndc
84606-6824
application_number
BLA125293
spl_id
c4d1b5ae-d085-4842-83d7-0a82bbadf094
active_ingredient_name
PEGLOTICASE
package_ndc
84606-6824-1
package_description
1800 mL in 1 BOTTLE, GLASS (84606-6824-1)
unii
R581OT55EA
spl_set_id
6e566303-d93a-4130-b764-25749829aa95
nui
N0000175670
pharm_class_epc
Uric Acid-specific Enzyme [EPC]
pharm_class
Urate Oxidase [CS]
pharm_class_cs
Urate Oxidase [CS]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class